Revenue rose 5.6% year-on-year to ₹8,853.3 crore from ₹8,382.1 crore, supported by development throughout companies. EBITDA declined 5% to ₹1,753 crore from ₹1,792 crore a 12 months earlier. EBITDA margin stood at 19.8% versus 21.4% within the 12 months-in the past interval.
The corporate’s European enterprise crossed €1 billion in annual revenue throughout FY26. Europe revenue for the quarter elevated 30.2% year-on-year to ₹2,795 crore (€261 million), pushed by efficiency throughout key markets. Development Markets revenue rose 24.7% year-on-year to ₹980 crore ($107 million), whereas ARV revenue elevated 6.4% to ₹328 crore ($36 million).
Additionally Learn: Aurobindo Pharma to launch ₹800 crore buyback at ₹1,475 per share from April 23
Analysis and improvement expenditure, together with depreciation, stood at ₹400 crore throughout the quarter, accounting for 4.5% of revenue. The corporate obtained ultimate approval for 9 ANDAs from the USFDA throughout the quarter.
Aurobindo Pharma mentioned it maintained a powerful net money place as of March 31, 2026, after cost of $317 million in direction of the acquisition of the Khandelwal Laboratories non-oncology enterprise. Free money movement era throughout the quarter stood at $35 million. Fundamental and diluted earnings per share stood at ₹15.86.
Formulations revenue elevated 4.6% year-on-year to ₹7,646 crore. US formulations revenue declined 13% year-on-year to ₹3,543 crore because of decrease transient sales and accounted for 40% of consolidated revenue.
As of March 31, 2026, the corporate had cumulatively filed 888 ANDAs with the USFDA and obtained 728 ultimate approvals and 35 tentative approvals. The corporate launched 12 merchandise throughout the quarter.
Additionally Learn: Aurobindo Pharma arm will get CDSCO advertising and marketing nod for Bevqolva
Europe formulations revenue rose 30.2% year-on-year to ₹2,795 crore and contributed 31.6% of consolidated revenue. In euro phrases, revenue elevated 10.8% year-on-year to €261 million.
Development Markets’ formulations revenue elevated 24.7% year-on-year to ₹980 crore and accounted for 11.1% of consolidated revenue. In greenback phrases, revenue rose 18.1% year-on-year to $107 million. Home formulation sales stood at ₹76 crore throughout the quarter, whereas FY26 revenue from the enterprise stood at ₹302 crore.
Antiretroviral (ARV) formulations revenue rose 6.4% year-on-year to ₹328 crore, contributing 3.7% of consolidated revenue. In greenback phrases, revenue elevated 1% year-on-year to $36 million.
Energetic Pharmaceutical Elements (API) revenue elevated 12.9% year-on-year to ₹1,208 crore and contributed 13.6% of consolidated revenue. In greenback phrases, API revenue rose 6.9% year-on-year to $132 million.
Ok Nithyananda Reddy, Vice-Chairman and Managing Director, mentioned, “We’re inspired by our efficiency for the quarter and the 12 months, reflecting the resilience of our enterprise mannequin and the power of our in depth product portfolio.
Additionally Learn: Aurobindo Pharma arm expands MSD pact, to take a position $150-175 million in new facility
Constant volumes coupled with improved working efficiencies and disciplined execution have contributed positively to our outcomes. With ongoing investments in capability enlargement and the stabilisation of just lately commercialised amenities, we stay assured in our capability to help sustainable development and create lengthy-time period worth for our stakeholders.”
Shares of Aurobindo Pharma Ltd ended at ₹1,546.45, up by ₹28.55, or 1.88%, on the BSE.
Source link
#Aurobindo #Pharma #net #revenue #revenue #rise #Europe #development #sales #decline #CNBC #TV18
